The latest trading day saw Viking Therapeutics, Inc. (VKTX) settling at $26.61, representing a +1.88% change from its previous close.

Discover why Altimmune (ALT) and Viking Therapeutics (VKTX) are top picks for high-risk investors. Click here to read my most ...

In a report released today, Andy Hsieh from William Blair maintained a Buy rating on Viking Therapeutics (VKTX – Research Report). The company’s shares closed today at $26.61.

Stocks: Real-time U.S. stock quotes reflect trades reported through ... Sources: FactSet, Tullett Prebon Commodities & Futures: Futures prices are delayed at least 10 minutes as per exchange ...

Viking Therapeutics Inc. Annual cash flow by ... Visit a quote page and your recently viewed tickers will be ... Real-time last sale data for U.S. stock quotes reflect trades reported through ...

Novo Nordisk NVO has seen strong momentum in recent years, driven by the commercial success of its blockbuster semaglutide ...

Growth investors have had to work harder than usual to find winners in 2025. With the S&P 500 essentially flat year to date ...

Eli Lilly is a global healthcare giant, generating strong growth from a diverse portfolio of blockbuster medications. Viking ...

Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company’s lead drug candidate is ...